Phase 3 to Commercial.
Confidence in getting your product to market.
Collaborative and science-led
Scale-up and validation.
Our team of experts can support you in navigating the challenges of Phase 3 to commercialisation.
Collaboration across all layers of our business ensures regulatory and quality control excellence, alongside the capabilities to manufacture at scale.
Over 25 years experience
Leadership team expertise.
Our leadership team has extensive experience in understanding the challenges of getting our clients from pre-clinical to late-phase manufacturing.
With a unique approach to project delivery and member of our Executive Leadership Team on every project, you can be confident in knowing your project is in good hands.
Frequently Asked Questions
Here are some frequently asked questions about late phase
How do you optimise your CDMO services to meet Phase 2 clinical trials requirements?
At Upperton, we understand that Phase 2 trials are crucial for validating the therapeutic potential identified in Phase 1. Our specialised services are designed to manage the increased complexity and stakes of this phase. We offer:
- Refined Formulation Development: Leveraging Phase 1 data, we optimize formulations to enhance efficacy, minimize side effects, and improve patient adherence.
- Scalable Manufacturing Solutions: As you transition to mid-scale manufacturing, we ensure consistent quality while maintaining the flexibility to adapt based on trial results.
- Expert Regulatory Guidance: We provide tailored support to navigate the specific regulatory requirements of Phase 2, ensuring compliance and thorough documentation.
Can Upperton provide regulatory support during Phase 2?
Yes, our regulatory affairs support service includes expert guidance, detailed documentation support regarding regulatory submissions, IND amendments and briefing packages.
Get in touch
If you’re looking to work with a CDMO that is flexible and nimble, then we’re here to help.
